Filing Flows › Regenerative Medical Technology Group (RMTG) › Q2 2025
Regenerative Medical Technology Group (RMTG) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 19, 2025
Regenerative Medical Technology Group (RMTG) reported revenue of $983K for the second quarter 2025 (Q2 2025), +24% from a year earlier and -28% from the quarter before. Operating margin was -25.4%, net loss $1.3M (132.8% of revenue).
Regenerative Medical Technology Group, Q2 2025: revenue $983K (+24% year over year), operating margin -25.4%, net loss $1.3M, operating cash flow −$598K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $983K | -28% | +24% |
| Operating profit | −$250K | -285% | — |
| Net earnings | −$1.3M | — | — |
| Operating cash flow | −$598K | -1147% | — |
What changed
Revenue was $1.0M in Q2 2025, up 24% year over year and down 28% from the previous quarter.
Gross margin was 59.6%, down 6.9 points from a year earlier. Operating costs exceeded revenue by $250K, an operating margin of -25.4%. Operating expenses grew 13% against revenue growth of 24%. The fastest-growing cost line was Sales & marketing (+52%). The quarter ended with a net loss of $1.3M, wider than the previous quarter's $760K loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$598K. Non-cash charges added back $55K of depreciation and amortization. Working capital and other items added $653K.
Questions
What was Regenerative Medical Technology Group's revenue in the second quarter 2025?
Regenerative Medical Technology Group (RMTG) reported revenue of $983K for the second quarter 2025 (Q2 2025), +24% from a year earlier and -28% from the quarter before.
Was Regenerative Medical Technology Group profitable in the second quarter 2025?
Operating loss was $250K (-25.4% of revenue) and net loss $1.3M.
Source: Regenerative Medical Technology Group 10-Q on SEC EDGAR.